Evidence map›Paper›PMID 33278917›Full record

Observational studyThe Lancet. Public health2021

Detecting COVID-19 infection hotspots in England using large-scale self-reported data from a mobile application: a prospective, observational study.

Thomas Varsavsky, Mark S Graham, Liane S Canas, Sajaysurya Ganesh, Joan Capdevila Pujol, Carole H Sudre, Benjamin Murray, Marc Modat, M Jorge Cardoso, Christina M Astley and 11 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in The Lancet. Public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 4 pooled it
2.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 4 syntheses or guidelines pooled it, 94 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Observational
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 3 countries.

Thomas VarsavskySchool of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
Mark S GrahamSchool of Biomedical Engineering and Imaging Sciences, King's College London, London, UK. Electronic address: mark.graham@kcl.ac.uk.
Liane S CanasSchool of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
Sajaysurya GaneshZoe Global, London, UK.
Joan Capdevila PujolZoe Global, London, UK.
Carole H SudreSchool of Biomedical Engineering and Imaging Sciences, King's College London, London, UK; Medical Research Council Unit for Lifelong Health and Ageing, Department of Population Science and Experimental Medicine, and Centre for Medical Image Computing, Department of Computer Science, University College London, London, UK.
Benjamin MurraySchool of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
Marc ModatSchool of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
M Jorge CardosoSchool of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
Christina M AstleyDivision of Endocrinology and Computational Epidemiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
David A DrewClinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA.
Long H NguyenClinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA.
Tove FallDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Maria F GomezDepartment of Clinical Sciences, Lund University Diabetes Centre, Malmö, Sweden.
Paul W FranksGenetic and Molecular Epidemiology Unit, Lund University Diabetes Centre, Malmö, Sweden.
Andrew T ChanClinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA.
Richard DaviesZoe Global, London, UK.
Jonathan WolfZoe Global, London, UK.
Claire J StevesDepartment of Twin Research and Genetic Epidemiology, King's College London, London, UK.
Tim D SpectorDepartment of Twin Research and Genetic Epidemiology, King's College London, London, UK.
Sebastien OurselinSchool of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
King's College London · GBZOE (United Kingdom) · GBMassachusetts General Hospital · USLund University · SEBoston Children's Hospital · USUniversity College London · GBUppsala University · SE

Funding

Dietary strategies for rational manipulation of the gut microbiome in inflammatory bowel diseaseK23DK125838 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI NGUYEN, LONG H · 2020 to 2024
$1.0M
Impact of Aspirin on the Gut Microbiome and Mucosal MicroenvironmentK01DK120742 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI DREW, DAVID A · 2020 to 2024
$793k
Seasonal and Viral Determinants of Type 1 Diabetes Onset, Remission, and Glycemic ControlK23DK120899 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI ASTLEY, CHRISTINA M. · 2019 to 2021
$682k
Medical Research Council MR/M016560/1NIDDK NIH HHS K01 DK120742NIDDK NIH HHS K23 DK120899NIDDK NIH HHS K23 DK125838Wellcome TrustWellcome Trust WT213038/Z/18/Z
6 · The paper itself

Abstract

backgroundAs many countries seek to slow the spread of COVID-19 without reimposing national restrictions, it has become important to track the disease at a local level to identify areas in need of targeted intervention.

methodsIn this prospective, observational study, we did modelling using longitudinal, self-reported data from users of the COVID Symptom Study app in England between March 24, and Sept 29, 2020. Beginning on April 28, in England, the Department of Health and Social Care allocated RT-PCR tests for COVID-19 to app users who logged themselves as healthy at least once in 9 days and then reported any symptom. We calculated incidence of COVID-19 using the invited swab (RT-PCR) tests reported in the app, and we estimated prevalence using a symptom-based method (using logistic regression) and a method based on both symptoms and swab test results. We used incidence rates to estimate the effective reproduction number, R(t), modelling the system as a Poisson process and using Markov Chain Monte-Carlo. We used three datasets to validate our models: the Office for National Statistics (ONS) Community Infection Survey, the Real-time Assessment of Community Transmission (REACT-1) study, and UK Government testing data. We used geographically granular estimates to highlight regions with rapidly increasing case numbers, or hotspots.

findingsFrom March 24 to Sept 29, 2020, a total of 2 873 726 users living in England signed up to use the app, of whom 2 842 732 (98·9%) provided valid age information and daily assessments. These users provided a total of 120 192 306 daily reports of their symptoms, and recorded the results of 169 682 invited swab tests. On a national level, our estimates of incidence and prevalence showed a similar sensitivity to changes to those reported in the ONS and REACT-1 studies. On Sept 28, 2020, we estimated an incidence of 15 841 (95% CI 14 023-17 885) daily cases, a prevalence of 0·53% (0·45-0·60), and R(t) of 1·17 (1·15-1·19) in England. On a geographically granular level, on Sept 28, 2020, we detected 15 (75%) of the 20 regions with highest incidence according to government test data.

interpretationOur method could help to detect rapid case increases in regions where government testing provision is lower. Self-reported data from mobile applications can provide an agile resource to inform policy makers during a quickly moving pandemic, serving as a complementary resource to more traditional instruments for disease surveillance.

fundingZoe Global, UK Government Department of Health and Social Care, Wellcome Trust, UK Engineering and Physical Sciences Research Council, UK National Institute for Health Research, UK Medical Research Council and British Heart Foundation, Alzheimer's Society, Chronic Disease Research Foundation.

Indexed as

Disease HotspotMobile ApplicationsSelf ReportAdolescentAdultAgedCOVID-19EnglandFemaleHumansMaleMiddle AgedProspective StudiesPublic Health SurveillanceYoung Adult

Identifiers

PMID33278917
PMCPMC7785969
OpenAlexW3109901608

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.